ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Neuroimmunology start-up Tranquis Therapeutics launches with $30 million

by Ryan Cross
July 18, 2020 | APPEARED IN VOLUME 98, ISSUE 28

 

Tranquis Therapeutics has raised $30 million in series A funding to develop small-molecule therapies for neurodegenerative diseases. The San Mateo, California–based start-up aims to make compounds to boost metabolic pathways that are diminished in myeloid immune cells in people with neurodegenerative diseases. The strategy is based on the research of Stanford University immunologist Edgar Engleman. The firm’s initial programs will be for amyotrophic lateral sclerosis and frontotemporal dementia.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment